Cyclacel Pharmaceuticals Inc. (CYCC) announced Monday morning that preclinical data of CYC065 showed that it substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in murine and human lung cancer cells with known high metastatic potential.
from RTT - Before the Bell http://ift.tt/2owV1LO
via IFTTT
No comments:
Post a Comment